Additionally, the amplification of HER2 is proposed as a resistance mechanism to EGFR TKIs in NSCLC patients, and anti‐EGFR monoclonal antibody cetuximab in patients with colorectal cancer.55, 137, 141. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.